The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 11,500.00
Ask: 12,200.00
Change: 0.00 (0.00%)
Spread: 700.00 (6.087%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK survey finds rising unease about AstraZeneca COVID-19 vaccine

Wed, 28th Apr 2021 00:01

By Kate Kelland

LONDON, April 28 (Reuters) - British enthusiasm for the
AstraZeneca COVID-19 vaccine has faded in the past month,
reflecting rising unease about its possible links to rare
adverse side effects, though overall UK confidence in vaccines
is high, an updated survey has found.

The survey of almost 5,000 people showed a significant
increase in the proportion who said they want to be vaccinated
against COVID-19 as soon as possible, but also found that almost
a quarter of those asked now believe the AstraZeneca
vaccine causes blood clots – up from 13% last month.

Reports of possible links to very rare blood clots have
dented confidence in the AstraZeneca shot, which was developed
with Oxford University scientists and shown in trials to be 76%
effective at preventing symptomatic COVID-19.

More than a dozen European countries temporarily suspended
its use after reports of blood clots combined with low platelets
in a very small number of people who had received it. Many
countries have resumed using the shot, but with some
restrictions.

"The blood clot scare has affected how some of the
(UK)public view the AstraZeneca vaccine – but has not reduced
confidence in vaccines overall," said Bobby Duffy, director of
King's College London's Policy Institute which co-led the study.

"In fact, the trend has been towards increased commitment to
get vaccinated – and quickly – as the rollout has progressed so
well, with no sign of serious widespread problems."

Both the European Medicines Agency (EMA) and Britain's
Medicines and Healthcare Regulatory Agency (MHRA) have reviewed
the vaccine's safety in the wake of the blood clot reports. They
say no causal link has been established, and that the vaccine's
benefits in preventing COVID-19 far outweigh any risks.

The UK survey was conducted between April 1 and 16 and
covered 4,896 UK adults aged between 18 and 75. It was designed
as a follow-up to a study first conducted late last year to
track how and why views of COVID-19 vaccines have changed.

It found that 17% of respondents now say that if they had a
choice, they would prefer to have the AstraZeneca vaccine - down
from 24% towards the end of March.

It also found that the majority of those asked whether the
shot causes blood clots are most likely to say that claim is
false, or that they don't know whether it is true.
(Reporting by Kate Kelland, editing by Mark Heinrich)

More News
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.